Gene alterations associated with vaginal bleeding in women using levonorgestrel intrauterine system and subdermal implant with etonogestrel

Financing : FAPESP

Researcher: Dr. Cassia Raquel Teatin Juliato

Associated researches: Flávia Rocha Torelli; Ilza Maria Urbano Monteiro ; Luis Guillermo Bahamondes

Line of Research: Contraception

Associated Research: Gene alterations associated with vaginal bleeding in women using the levonorgestrel intrauterine system

Vaginal bleeding is the main reason for discontinuation in women using a levonogestrel-releasing intrauterine system (LNG-IUS). Currently, there is no test capable of predicting which woman will present an unsatisfactory menstrual pattern. Objective: To evaluate the gene expression profile of women using LNG-IUS who present or not with abnormal vaginal bleeding during the first year of use. Methods: 100 women who choose the LNG-IUS as a contraceptive method at the Family Planning outpatient clinic of CAISM/UNICAMP will be included. These women will undergo endometrial biopsy immediately prior to LNG-IUS placement and will be followed up for 1 year with assessment of bleeding pattern. After 12 months, gene expression will be evaluated, associated with inflammation genes (FKBP51, NR3C1, ADAMTS1, ADH1A, CLEC3B, VEGF, CYP3A4, NR1I2, NPTX1, SERPINE1, STC1) among women who had normal and abnormal bleeding, and no bleeding. For statistical analysis, the difference between endometrial gene expression will be used Ç2 test or Fisher’s exact test.

Area of knowledge: Health Sciences – Medicine – Maternal and Child Health